They found that YTHDF3 promoted the binding between eukaryotic initiation factor 3 and angiogenic transcripts, such as VEGFA and epidermal growth factor receptor (EGFR), indicating its potential role as a therapeutic target in breast cancer [29]. Here, EGFR is linked to breast carcinoma.